FDA Approves Casgevy Gene Therapy for Patients Aged 2 and Older

The FDA approved Casgevy for patients aged two and older with either sickle cell disease or transfusion-dependent beta thalassemia. This supplement allows treatment for children experiencing recurrent pain crises or requiring regular blood transfusions.